Triple-S Management Corporation
Triple-S Management Corporation (GTS) Stock Competitors & Peer Comparison
See (GTS) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Healthcare Plans Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| GTS | $35.99 | +1.04% | 0 | 10.41 | $3.46 | N/A |
| UNH | $393.85 | -1.31% | 357.4B | 29.64 | $13.28 | +2.26% |
| CVS | $95.89 | -1.30% | 122.3B | 42.04 | $2.28 | +2.76% |
| ANTM | $482.58 | +2.71% | 114.6B | 18.99 | $25.41 | +1.00% |
| ELV | $392.68 | -1.02% | 85.2B | 16.62 | $23.62 | +1.73% |
| CI | $285.27 | -3.28% | 75.5B | 11.24 | $25.38 | +2.12% |
| HUM | $305.12 | +1.25% | 36.7B | 32.61 | $9.36 | +1.16% |
| CNC | $58.27 | -0.73% | 28.8B | -4.46 | -$13.05 | N/A |
| MOH | $184.99 | -0.97% | 9.6B | 51.08 | $3.62 | N/A |
| OSCR | $23.32 | +0.73% | 6B | -43.17 | -$0.54 | N/A |
Stock Comparison
GTS vs UNH Comparison May 2026
GTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GTS stands at 0. In comparison, UNH has a market cap of 357.4B. Regarding current trading prices, GTS is priced at $35.99, while UNH trades at $393.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GTS currently has a P/E ratio of 10.41, whereas UNH's P/E ratio is 29.64. In terms of profitability, GTS's ROE is +0.07%, compared to UNH's ROE of +0.12%. Regarding short-term risk, GTS is less volatile compared to UNH. This indicates potentially lower risk in terms of short-term price fluctuations for GTS.Check UNH's competition here
GTS vs CVS Comparison May 2026
GTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GTS stands at 0. In comparison, CVS has a market cap of 122.3B. Regarding current trading prices, GTS is priced at $35.99, while CVS trades at $95.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GTS currently has a P/E ratio of 10.41, whereas CVS's P/E ratio is 42.04. In terms of profitability, GTS's ROE is +0.07%, compared to CVS's ROE of +0.04%. Regarding short-term risk, GTS is less volatile compared to CVS. This indicates potentially lower risk in terms of short-term price fluctuations for GTS.Check CVS's competition here
GTS vs ANTM Comparison May 2026
GTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GTS stands at 0. In comparison, ANTM has a market cap of 114.6B. Regarding current trading prices, GTS is priced at $35.99, while ANTM trades at $482.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GTS currently has a P/E ratio of 10.41, whereas ANTM's P/E ratio is 18.99. In terms of profitability, GTS's ROE is +0.07%, compared to ANTM's ROE of +0.12%. Regarding short-term risk, GTS is less volatile compared to ANTM. This indicates potentially lower risk in terms of short-term price fluctuations for GTS.Check ANTM's competition here
GTS vs ELV Comparison May 2026
GTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GTS stands at 0. In comparison, ELV has a market cap of 85.2B. Regarding current trading prices, GTS is priced at $35.99, while ELV trades at $392.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GTS currently has a P/E ratio of 10.41, whereas ELV's P/E ratio is 16.62. In terms of profitability, GTS's ROE is +0.07%, compared to ELV's ROE of +0.12%. Regarding short-term risk, GTS is less volatile compared to ELV. This indicates potentially lower risk in terms of short-term price fluctuations for GTS.Check ELV's competition here
GTS vs CI Comparison May 2026
GTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GTS stands at 0. In comparison, CI has a market cap of 75.5B. Regarding current trading prices, GTS is priced at $35.99, while CI trades at $285.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GTS currently has a P/E ratio of 10.41, whereas CI's P/E ratio is 11.24. In terms of profitability, GTS's ROE is +0.07%, compared to CI's ROE of +0.15%. Regarding short-term risk, GTS is less volatile compared to CI. This indicates potentially lower risk in terms of short-term price fluctuations for GTS.Check CI's competition here
GTS vs HUM Comparison May 2026
GTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GTS stands at 0. In comparison, HUM has a market cap of 36.7B. Regarding current trading prices, GTS is priced at $35.99, while HUM trades at $305.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GTS currently has a P/E ratio of 10.41, whereas HUM's P/E ratio is 32.61. In terms of profitability, GTS's ROE is +0.07%, compared to HUM's ROE of +0.06%. Regarding short-term risk, GTS is less volatile compared to HUM. This indicates potentially lower risk in terms of short-term price fluctuations for GTS.Check HUM's competition here
GTS vs CNC Comparison May 2026
GTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GTS stands at 0. In comparison, CNC has a market cap of 28.8B. Regarding current trading prices, GTS is priced at $35.99, while CNC trades at $58.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GTS currently has a P/E ratio of 10.41, whereas CNC's P/E ratio is -4.46. In terms of profitability, GTS's ROE is +0.07%, compared to CNC's ROE of -0.29%. Regarding short-term risk, GTS is less volatile compared to CNC. This indicates potentially lower risk in terms of short-term price fluctuations for GTS.Check CNC's competition here
GTS vs MOH Comparison May 2026
GTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GTS stands at 0. In comparison, MOH has a market cap of 9.6B. Regarding current trading prices, GTS is priced at $35.99, while MOH trades at $184.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GTS currently has a P/E ratio of 10.41, whereas MOH's P/E ratio is 51.08. In terms of profitability, GTS's ROE is +0.07%, compared to MOH's ROE of +0.04%. Regarding short-term risk, GTS is less volatile compared to MOH. This indicates potentially lower risk in terms of short-term price fluctuations for GTS.Check MOH's competition here
GTS vs OSCR Comparison May 2026
GTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GTS stands at 0. In comparison, OSCR has a market cap of 6B. Regarding current trading prices, GTS is priced at $35.99, while OSCR trades at $23.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GTS currently has a P/E ratio of 10.41, whereas OSCR's P/E ratio is -43.17. In terms of profitability, GTS's ROE is +0.07%, compared to OSCR's ROE of -0.03%. Regarding short-term risk, GTS is less volatile compared to OSCR. This indicates potentially lower risk in terms of short-term price fluctuations for GTS.Check OSCR's competition here
GTS vs ALHC Comparison May 2026
GTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GTS stands at 0. In comparison, ALHC has a market cap of 3.3B. Regarding current trading prices, GTS is priced at $35.99, while ALHC trades at $15.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GTS currently has a P/E ratio of 10.41, whereas ALHC's P/E ratio is 157.30. In terms of profitability, GTS's ROE is +0.07%, compared to ALHC's ROE of +0.11%. Regarding short-term risk, GTS is less volatile compared to ALHC. This indicates potentially lower risk in terms of short-term price fluctuations for GTS.Check ALHC's competition here
GTS vs CLOV Comparison May 2026
GTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GTS stands at 0. In comparison, CLOV has a market cap of 1.8B. Regarding current trading prices, GTS is priced at $35.99, while CLOV trades at $3.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GTS currently has a P/E ratio of 10.41, whereas CLOV's P/E ratio is -26.69. In terms of profitability, GTS's ROE is +0.07%, compared to CLOV's ROE of -0.17%. Regarding short-term risk, GTS is less volatile compared to CLOV. This indicates potentially lower risk in terms of short-term price fluctuations for GTS.Check CLOV's competition here
GTS vs BHG Comparison May 2026
GTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GTS stands at 0. In comparison, BHG has a market cap of 130.5M. Regarding current trading prices, GTS is priced at $35.99, while BHG trades at $16.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GTS currently has a P/E ratio of 10.41, whereas BHG's P/E ratio is -0.12. In terms of profitability, GTS's ROE is +0.07%, compared to BHG's ROE of -0.70%. Regarding short-term risk, GTS is less volatile compared to BHG. This indicates potentially lower risk in terms of short-term price fluctuations for GTS.Check BHG's competition here
GTS vs CABR Comparison May 2026
GTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GTS stands at 0. In comparison, CABR has a market cap of 13.9M. Regarding current trading prices, GTS is priced at $35.99, while CABR trades at $0.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GTS currently has a P/E ratio of 10.41, whereas CABR's P/E ratio is -2.04. In terms of profitability, GTS's ROE is +0.07%, compared to CABR's ROE of -3.00%. Regarding short-term risk, GTS is less volatile compared to CABR. This indicates potentially lower risk in terms of short-term price fluctuations for GTS.Check CABR's competition here
GTS vs BMGL Comparison May 2026
GTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GTS stands at 0. In comparison, BMGL has a market cap of 12.3M. Regarding current trading prices, GTS is priced at $35.99, while BMGL trades at $0.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GTS currently has a P/E ratio of 10.41, whereas BMGL's P/E ratio is -1.46. In terms of profitability, GTS's ROE is +0.07%, compared to BMGL's ROE of -1.95%. Regarding short-term risk, GTS is less volatile compared to BMGL. This indicates potentially lower risk in terms of short-term price fluctuations for GTS.Check BMGL's competition here
GTS vs MRAI Comparison May 2026
GTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GTS stands at 0. In comparison, MRAI has a market cap of 5M. Regarding current trading prices, GTS is priced at $35.99, while MRAI trades at $0.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GTS currently has a P/E ratio of 10.41, whereas MRAI's P/E ratio is -0.09. In terms of profitability, GTS's ROE is +0.07%, compared to MRAI's ROE of +0.52%. Regarding short-term risk, GTS is less volatile compared to MRAI. This indicates potentially lower risk in terms of short-term price fluctuations for GTS.Check MRAI's competition here
GTS vs UAM Comparison May 2026
GTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GTS stands at 0. In comparison, UAM has a market cap of 0. Regarding current trading prices, GTS is priced at $35.99, while UAM trades at $1.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GTS currently has a P/E ratio of 10.41, whereas UAM's P/E ratio is N/A. In terms of profitability, GTS's ROE is +0.07%, compared to UAM's ROE of +0.17%. Regarding short-term risk, GTS is more volatile compared to UAM. This indicates potentially higher risk in terms of short-term price fluctuations for GTS.Check UAM's competition here
GTS vs AET Comparison May 2026
GTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GTS stands at 0. In comparison, AET has a market cap of 0. Regarding current trading prices, GTS is priced at $35.99, while AET trades at $106.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GTS currently has a P/E ratio of 10.41, whereas AET's P/E ratio is N/A. In terms of profitability, GTS's ROE is +0.07%, compared to AET's ROE of +0.11%. Regarding short-term risk, GTS is more volatile compared to AET. This indicates potentially higher risk in terms of short-term price fluctuations for GTS.Check AET's competition here
GTS vs MGLN Comparison May 2026
GTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GTS stands at 0. In comparison, MGLN has a market cap of 0. Regarding current trading prices, GTS is priced at $35.99, while MGLN trades at $94.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GTS currently has a P/E ratio of 10.41, whereas MGLN's P/E ratio is 8.49. In terms of profitability, GTS's ROE is +0.07%, compared to MGLN's ROE of +0.00%. Regarding short-term risk, GTS is more volatile compared to MGLN. This indicates potentially higher risk in terms of short-term price fluctuations for GTS.Check MGLN's competition here